Navigation Links
The Emerging Eastern European Market For Interventional Cardiology Devices Will Grow To $282 Million By 2021

TORONTO, July 18, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, markets for interventional cardiology (IC) devices have reached maturation in Belgium, Sweden, Switzerland and the Netherlands, while Eastern European markets will continue to see growth. Procedure volume growth will be slight in Belgium, Sweden, Switzerland and the Netherlands through 2021 because IC procedures are well accepted and have high adoption in these countries. In contrast, Eastern European markets, including the Czech Republic, Hungary, Poland and Romania will see higher growth in procedure volumes as the use of interventional cardiology becomes more widespread.


Despite the European Union's attempts to harmonize prices, they will continue to differ greatly between countries. This has resulted in cross-border purchasing as facilities try to take advantage of lower device costs in neighboring countries. For example, a stent costs more than four times as much in the Czech Republic as it does in Poland, and therefore many Czech hospitals will engage in cross-border purchasing to combat high prices.

"Countries such as Romania, the Czech Republic, Hungary and Switzerland are seeing very high stent prices, especially for more advanced products such as drug-eluting stents (DES)," said MRG Senior Analyst Ian Swanson. "Many European governments are attempting to drive down prices by using group purchasing tactics such as those that have seen success in Germany. This makes devices more affordable to consumers and government payers, although it limits revenues for manufacturers competing in the European IC device market."

Falling prices will offset procedure volume growth in Belgium, Sweden, Switzerland and the Netherlands, and as a result, these markets will decline before stabilizing in 2018. Although prices will also decline in Eastern Europe, higher procedure volume growth will lead to modest market expansion through 2021.

Millennium Research Group's Eastern European Markets for Interventional Cardiology Devices 2013 and European Markets for Interventional Cardiology Devices 2013 (Part 2) reports include unit, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, accessory devices, intravascular imaging catheters and pressure guidewires in the Czech Republic, Hungary, Poland, Romania, Belgium, Sweden, Switzerland and the Netherlands. Supplemental country coverage is also available for Austria, Denmark, Finland, Greece, Norway, Poland, Portugal and Ukraine, as well as in aggregate for the rest of the European countries.

About Millennium Research Group
Millennium Research Group (, a Decision Resources Group company (, is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group

Alex Jablokow
Millennium Research Group

SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
2. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
3. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
4. Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show
5. Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer
6. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
7. NextDocs Launches QuickStart for Emerging Growth Companies
8. Treatment Adherence Emerging as Critical Theme in Improving Quality and Cost of US Healthcare
9. For Treatment of Extensive-Disease Small-Cell Lung Cancer (ED-SCLC), No Emerging Therapy is Likely to Replace Etoposide/Carboplatin as the Standard of Care Before 2022
10. Details of New Synthetic Vaccine for Emerging H7N9 Threat Revealed at BIO International Convention in Chicago, April 22-25
11. GlaxoSmithKline and A*STARs Institute of Chemical Engineering and Sciences to Develop new Medicines for Emerging Markets
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of ... 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session on ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the ... LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making the ... a version of Asterisk that will receive not only security fixes, but feature ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
Breaking Medicine News(10 mins):